Meropenem Hikma (Meropenem Anhydrous)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, blocking the final step of peptidoglycan cross‑linking. This inhibition compromises cell‑wall integrity, leading to osmotic lysis and rapid bacterial death across a broad spectrum of Gram‑positive, Gram‑negative and anaerobic organisms.

The dosing regimen for Meropenem Hikma is determined by the prescribing clinician based on the type and severity of infection, patient age, weight, renal function and local antimicrobial guidelines. No fixed dose is provided here; the prescriber will calculate the appropriate amount and frequency.

Limited clinical data exist for Meropenem use during pregnancy and lactation. It should be prescribed only when the potential therapeutic benefit justifies any potential risk to the fetus or infant. Healthcare providers should discuss the risk‑benefit profile with the patient and consider alternative agents when appropriate.

To place an order, submit an enquiry on the Meropenem Hikma product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Meropenem shares the broad‑spectrum activity typical of carbapenems but offers a slightly wider coverage against Pseudomonas aeruginosa and many extended‑spectrum β‑lactamase‑producing organisms compared with imipenem. It is generally well tolerated, though like other carbapenems it carries a risk of seizures in patients with renal impairment.

Meropenem Hikma should be stored below 25 °C in its original container, protected from moisture and light. After reconstitution, the solution must be used promptly according to the manufacturer’s instructions and any unused portion discarded in accordance with local regulations.

Meropenem is supplied as a sterile powder for solution and is administered intravenously. The reconstituted solution is infused over a prescribed period, typically 15–30 minutes, under aseptic conditions. Administration details, including infusion rate and dilution, are determined by the treating physician.

Serious adverse events include seizures (especially in patients with renal dysfunction or pre‑existing CNS disease), severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, marked neutropenia or thrombocytopenia, acute renal failure, and rare dermatologic reactions like Stevens‑Johnson syndrome.

Meropenem is contraindicated in individuals with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for patients with a history of seizures, severe renal impairment, or those receiving concomitant medications that lower the seizure threshold.